Drug intelligence / Profile preview

influenza vaccine live attenuated trivalent + influenza vaccine inactivated trivalent

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Vaccines & Immunotherapeutics
Administration
Intranasal, Intramuscular
01

Overview

CAIV-T + TIV refers to the comparative evaluation or co-administration context of the Cold-Adapted Influenza Vaccine, Trivalent (CAIV-T) and the Trivalent Inactivated Influenza Vaccine (TIV). CAIV-T, marketed as FluMist, is a live attenuated, refrigerator-stable vaccine administered intranasally, designed to mimic natural infection and induce mucosal immunity. TIV is the traditional injectable vaccine containing inactivated viral components. These two vaccine types were compared in a pivotal Phase 3 trial (NCT00192257) involving children and adolescents with asthma, where CAIV-T demonstrated superior efficacy in preventing culture-confirmed influenza compared to TIV without increasing asthma-related adverse events.

Brand names
FluMist
Other names
CAIV-T + TIVCold-Adapted Influenza Vaccine, Trivalent + Trivalent Inactivated Influenza Vaccine
02

Targets

NeuraminidaseHA (Hemagglutinin)

Beyond the preview

Go deeper on influenza vaccine live attenuated trivalent + influenza vaccine inactivated trivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza vaccine live attenuated trivalent + influenza vaccine inactivated trivalent.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call